OC
LUCD icon

Oppenheimer & Co’s Lucid Diagnostics LUCD Stock Holding History

Oppenheimer & Co’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.5K Buy
+30,000
New +$38.2K ﹤0.01% 1673

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Oppenheimer & Co's LUCD Position: Q1 2026 in Review

Oppenheimer & Co opened a new position in Lucid Diagnostics (LUCD) in Q1 2026: 30,000 shares worth $34.5K. The stake represents ﹤0.01% of the portfolio and ranks #1673 among its holdings.

103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Oppenheimer & Co held 30,000 shares of Lucid Diagnostics worth $34.5K as of Q1 2026.
  • Lucid Diagnostics was a new Oppenheimer & Co position in Q1 2026.
  • Lucid Diagnostics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1673 holding.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.